amantadine has been researched along with Tremor in 55 studies
amant: an antiviral compound consisting of an adamantane derivative chemically linked to a water-solube polyanioic matrix; structure in first source
Tremor: Cyclical movement of a body part that can represent either a physiologic process or a manifestation of disease. Intention or action tremor, a common manifestation of CEREBELLAR DISEASES, is aggravated by movement. In contrast, resting tremor is maximal when there is no attempt at voluntary movement, and occurs as a relatively frequent manifestation of PARKINSON DISEASE.
| Excerpt | Relevance | Reference |
|---|---|---|
| " In more than 50 percent of the cases of initial tremor induced by lithium therapy, oxprenolol in daily doses of 160--240 mg produced good effects and moderate improvement was noted in a few further cases." | 9.04 | Therapy of extrapyramidal side effects, with particular reference to persistent dyskinesia and lithium tremor. ( Pöldinger, W, 1978) |
| "The effects of anticholinergic and dopaminergic drugs used for Parkinson's disease were studied on the tremor induced by physostigmine (0." | 7.66 | Drugs for Parkinson's disease reduce tremor induced by physostigmine. ( Fincke, M; Gothóni, P; Lehtinen, M, 1983) |
| "Administration of oxotremorine to mice produced centrally-mediated effects, such as catalepsy and tremor, and peripheral muscarinic actions, such as diarrhoea and lachrymation." | 7.66 | Amantadine antagonism of oxotremorine effects. ( Eshel, Y; Korczyn, AD, 1979) |
| " In more than 50 percent of the cases of initial tremor induced by lithium therapy, oxprenolol in daily doses of 160--240 mg produced good effects and moderate improvement was noted in a few further cases." | 5.04 | Therapy of extrapyramidal side effects, with particular reference to persistent dyskinesia and lithium tremor. ( Pöldinger, W, 1978) |
| "The relative efficacy of trihexiphenidyl hydrochloride, amantadine hydrochloride, and low-dose carbidopa-levodopa in reducing parkinsonian tremor was investigated using objective techniques." | 3.67 | Pharmacologic treatment of parkinsonian tremor. ( Koller, WC, 1986) |
| "The effects of anticholinergic and dopaminergic drugs used for Parkinson's disease were studied on the tremor induced by physostigmine (0." | 3.66 | Drugs for Parkinson's disease reduce tremor induced by physostigmine. ( Fincke, M; Gothóni, P; Lehtinen, M, 1983) |
| "Administration of oxotremorine to mice produced centrally-mediated effects, such as catalepsy and tremor, and peripheral muscarinic actions, such as diarrhoea and lachrymation." | 3.66 | Amantadine antagonism of oxotremorine effects. ( Eshel, Y; Korczyn, AD, 1979) |
| "Amantadine-induced tremor has been investigated using mice." | 3.65 | Amantadin e tremor, a 5-hydroxytryptamine-mediated response? ( Cox, B; Tha, SJ, 1975) |
| "We have studied the urinary excretion of 1,4-methylhistamine (1,4-MeHm), 5-hydroxyindole-3-acetic acid (5-HIAA) and homovanillic acid (HVA) in patients with Parkinson's disease, choreiform movements and essential tremor." | 3.65 | Urinary monoamine metabolite excretion in disorders of movement. Effects of amantadine and levodopa. ( Fleming, AM; Lenman, JA; Reid, A; Turnbull, MJ, 1977) |
| "Amantadine was moderately effective, but cyproheptadine, diphenhydramine, and benztropine gave little or no relief." | 2.65 | Treatment of valproate tremors. ( Bauman, AW; Hammond, EJ; Karas, BJ; Wilder, BJ, 1983) |
| " Dextroamphetamine in lower dosage also reduced disability by some 17 percent." | 2.64 | Amphetamines in the treatment of Parkinson's disease. ( Asselman, P; Bovill, KT; Marsden, CD; Parkes, JD; Phipps, JA; Rose, P; Tarsy, D, 1975) |
| "ET tremor is usually characterized by symmetric bilateral postural and kinetic tremor, which may respond to low alcohol consumption." | 2.44 | [Diagnosis and treatment of tremor in Parkinson's disease and essential tremor]. ( Benecke, R; Wolters, A, 2007) |
| "Tremor-predominant Parkinson's disease is characterised by prominent tremor of one or more limbs with a relative lack of significant rigidity and bradykinesia." | 2.41 | Tremor-predominant Parkinson's disease. Approaches to treatment. ( Koller, W; Marjama-Lyons, J, 2000) |
| "Midbrain tremor is a resting, postural, action and intentional tremor of the upper extremity." | 1.38 | Midbrain tremor: a tremor resistant to treatment. ( Badar, Z; Rana, AQ, 2012) |
| "This article gives an overview of Parkinson's disease, a common neurological disorder." | 1.27 | Comprehensive care of the patient with Parkinson's disease. ( Bratton, M; Jost, MG; Lannon, MC; Lockhart-Pretti, P; Thomas, CA, 1986) |
| "Resting tremor is present when the hands are at rest; it disappears with movement." | 1.26 | The shaking patient. Diagnosis and management of tremor. ( McKinney, AS, 1977) |
| "Twenty-seven patients with Parkinson's disease participated in a double-blind crossover trial of L-dopa and amantadine." | 1.25 | Interactions of L-dopa and amantadine in patients with Parkinsonism. ( Cox, B; Danta, G; Schnieden, H; Yuill, GM, 1973) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 47 (85.45) | 18.7374 |
| 1990's | 1 (1.82) | 18.2507 |
| 2000's | 5 (9.09) | 29.6817 |
| 2010's | 2 (3.64) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hamonet, C | 1 |
| Césaro, P | 1 |
| Michalski, LS | 1 |
| Hantsch Bardsley, C | 1 |
| Holt, DR | 1 |
| Milner, JE | 1 |
| Hou, SH | 1 |
| Rana, AQ | 1 |
| Badar, Z | 1 |
| Takahashi, H | 1 |
| Shinohara, Y | 2 |
| Wolters, A | 1 |
| Benecke, R | 1 |
| Hayakawa, N | 1 |
| Jörg, J | 1 |
| Karas, BJ | 1 |
| Wilder, BJ | 1 |
| Hammond, EJ | 1 |
| Bauman, AW | 1 |
| Koller, WC | 2 |
| Gothóni, P | 1 |
| Lehtinen, M | 1 |
| Fincke, M | 1 |
| Schneider, E | 1 |
| Fischer, PA | 1 |
| Clemens, R | 1 |
| Balzereit, F | 1 |
| Fünfgeld, EW | 1 |
| Haase, HJ | 1 |
| Manyam, BV | 1 |
| Marjama-Lyons, J | 1 |
| Koller, W | 1 |
| Hungerbühler, JP | 1 |
| Regli, F | 1 |
| Pöldinger, W | 1 |
| Przuntek, H | 1 |
| Cox, B | 2 |
| Tha, SJ | 1 |
| Eshel, Y | 1 |
| Korczyn, AD | 1 |
| Pearlman, JT | 1 |
| Kadish, AH | 1 |
| Ramseyer, JC | 1 |
| Butzer, JF | 1 |
| Silver, DE | 1 |
| Sahs, AL | 1 |
| McKinney, AS | 1 |
| Lenman, JA | 1 |
| Turnbull, MJ | 1 |
| Reid, A | 1 |
| Fleming, AM | 1 |
| Parkes, JD | 1 |
| Tarsy, D | 1 |
| Marsden, CD | 1 |
| Bovill, KT | 1 |
| Phipps, JA | 1 |
| Rose, P | 1 |
| Asselman, P | 1 |
| Schubert, U | 1 |
| Fischer, GJ | 1 |
| Glass, J | 1 |
| Strong, DK | 1 |
| Eisenstat, DD | 1 |
| Bryson, SM | 1 |
| Sitar, DS | 1 |
| Arbus, GS | 1 |
| Lannon, MC | 1 |
| Thomas, CA | 1 |
| Bratton, M | 1 |
| Jost, MG | 1 |
| Lockhart-Pretti, P | 1 |
| Obeso, JA | 1 |
| Luquín, MR | 1 |
| Artieda, J | 1 |
| Martinez-Lage, JM | 1 |
| Klawans, HL | 1 |
| Topel, JL | 1 |
| Campbell, AM | 1 |
| Williams, MJ | 1 |
| Potvin, AR | 1 |
| Albers, JW | 1 |
| Repa, BS | 1 |
| Henderson, WG | 1 |
| Walker, JE | 1 |
| Stribley, RF | 1 |
| Tourtellotte, WW | 1 |
| Iivanainen, M | 2 |
| Meyerson, B | 1 |
| Schwab, RS | 2 |
| Poskanzer, DC | 1 |
| England, AC | 1 |
| Young, RR | 2 |
| Harper, RW | 1 |
| Knothe, BU | 1 |
| Danta, G | 1 |
| Schnieden, H | 1 |
| Yuill, GM | 1 |
| Stern, P | 1 |
| Srebocan, S | 1 |
| Cvetnić, S | 1 |
| Brmalj, V | 1 |
| Chase, TN | 1 |
| Woods, AC | 1 |
| Glaubiger, GA | 1 |
| Mori, J | 1 |
| Sato, Y | 1 |
| Oashi, T | 1 |
| Hitomi, M | 1 |
| Bauer, RB | 1 |
| McHenry, JT | 1 |
| Dallos, V | 1 |
| Heathfield, K | 1 |
| Stone, P | 1 |
| Allen, FA | 1 |
| Appleton, DB | 1 |
| Eadie, MJ | 1 |
| Sutherland, JM | 1 |
| Rao, NS | 1 |
| Pearce, J | 1 |
| Freedman, BE | 1 |
| Getz, E | 1 |
| MacGregor, JM | 1 |
| Ames, FR | 1 |
| Mann, DC | 1 |
| Pearce, LA | 1 |
| Waterbury, LD | 1 |
| Giuffrè, R | 1 |
| Gambacorta, D | 1 |
| Critchley, E | 1 |
| Jurna, I | 1 |
| Grossmann, W | 1 |
| Nell, T | 1 |
| Agnoli, A | 1 |
| Casacchia, M | 1 |
| Ruggieri, S | 1 |
| Volante, F | 1 |
| Accornero, N | 1 |
| Hartmann-von Monakow, K | 1 |
| Lutz, EG | 1 |
| Völler, GW | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Open-Label Safety Study of ADS-5102 (Amantadine HCl) Extended Release Capsules for the Treatment of Levodopa Induced Dyskinesia (LID)[NCT02202551] | Phase 3 | 223 participants (Actual) | Interventional | 2014-07-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"To evaluate clinical progression of PD as assessed by the MDS-UPDRS, combined score, Parts I, II, and III.~Part I - non-motor experiences of daily living; Part II - motor experiences of daily living; Part III - motor examination. Parts I and II each contain 13 questions measured on a 5-point scale (0-4). Part III contains 18 objective rater assessments of the motor signs of PD measured on a 5-point scale (0-4).~Total range for combined score (Part I-III) is = 0-176. Generally for MDS-UPDRS scores and sub-scores, the lower the score, the better.~Parts I, II, and III are summed to make the total score." (NCT02202551)
Timeframe: Up to 101 weeks. MDS-UPDRS was performed at the following visits: Screening, Week 8, Week 16, Week 28, Week 40, Week 52, Week 64, Week 76, Week 88, Week 100 (or ET).
| Intervention | units on a scale (Mean) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Baseline | Change from Baseline at Week 8 | Change from Baseline at Week 16 | Change from Baseline at Week 28 | Change from Baseline at Week 40 | Change from Baseline at Week 52 | Change from Baseline at Week 64 | Change from Baseline at Week 76 | Change from Baseline at Week 88 | Change from Baseline at Week 100 | |
| ADS-5102 1A | 41.8 | 1.2 | 1.6 | 4.8 | 7.5 | 13.2 | 8.8 | 11.7 | 11.3 | 11.4 |
| ADS-5102 Group 1P | 45.6 | -2.8 | -1.4 | 1.5 | -0.4 | 2.6 | 2.6 | 7.3 | 3.7 | 3.7 |
| ADS-5102 Group 2 | 52.8 | 0.8 | 5.7 | 6.5 | 1.6 | 6.1 | 6.1 | 9.4 | 6.4 | 6.5 |
| ADS-5102 Group 3 | 52.4 | -5.3 | -5.2 | -5.3 | -4.8 | -4.6 | -4.6 | -4.9 | 0.9 | 4.1 |
"This component (Questions 4.1 - 4.6) includes time spent with dyskinesia, functional impact of dyskinesia, time spent in OFF state, functional impact of fluctuations, complexity of motor fluctuations, painful OFF-state dystonia. Questions 4.1-4.6 are summed to make the Part IV score.~Generally for MDS-UPDRS scores and sub-scores, the lower the score, the better. Total range for Part IV is = 0-24" (NCT02202551)
Timeframe: 100 Weeks. MDS-UPDRS was performed at the following visits: Screening, Week 8, Week 16, Week 28, Week 40, Week 52, Week 64, Week 76, Week 88, Week 100 (or ET).
| Intervention | units on a scale (Mean) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Baseline | Change in Baseline from Week 8 | Change in Baseline from Week 16 | Change from Baseline at Week 28 | Change from Baseline at Week 40 | Change from Baseline at Week 52 | Change from Baseline at Week 64 | Change from Baseline at Week 76 | Change from Baseline at Week 88 | Change from Baseline at Week 100 | |
| Group 1a | 6.5 | -0.2 | -0.8 | -0.3 | 0.0 | 0.2 | 0.4 | 0.9 | 0.4 | 0.4 |
| Group 1P | 9.6 | -3.4 | -3.2 | -3.3 | -2.8 | -2.9 | -3.3 | -2.9 | -2.8 | -2.4 |
| Group 2 | 9.8 | -3.6 | -1.1 | -1.4 | -2.9 | -2.5 | -1.9 | -2.7 | -3.7 | -3.6 |
| Group 3 | 10.4 | -4.0 | -3.9 | -4.4 | -4.7 | -3.6 | -2.5 | -3.7 | -4.3 | -3.6 |
The primary objective of the study was to evaluate the safety and tolerability of ADS-5102 oral capsules, an extended release (ER) formulation of amantadine, administered at a dose of 340 mg once daily at bedtime for the treatment of levodopa-induced dyskinesia (LID) in subjects with Parkinson's disease (PD). (NCT02202551)
Timeframe: Up to 101 weeks
| Intervention | Participants (Count of Participants) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| AE | Study drug-related AE | SAEs | Permanent discontinuation due to AE | Permanent discontinuation due to drug-related AE | Mild AEs | Moderate AEs | Mild drug-related AE | Moderate drug-related AE | Severe drug-related AE | |
| Group 1a | 57 | 31 | 16 | 12 | 4 | 12 | 25 | 16 | 12 | 3 |
| Group 1P | 70 | 45 | 21 | 21 | 15 | 13 | 36 | 15 | 23 | 7 |
| Group 2 | 23 | 16 | 6 | 6 | 4 | 3 | 13 | 3 | 12 | 1 |
| Group 3 | 55 | 32 | 17 | 10 | 8 | 11 | 26 | 5 | 22 | 5 |
6 reviews available for amantadine and Tremor
| Article | Year |
|---|---|
[Diagnosis and therapy for patients with vascular parkinsonism].
Topics: Akinetic Mutism; Amantadine; Antiparkinson Agents; Cerebral Infarction; Dementia, Vascular; Diagnosi | 2003 |
[Diagnosis and treatment of tremor in Parkinson's disease and essential tremor].
Topics: Adrenergic beta-Antagonists; Amantadine; Anticonvulsants; Antiparkinson Agents; Deep Brain Stimulati | 2007 |
Tremor-predominant Parkinson's disease. Approaches to treatment.
Topics: Acetates; Amantadine; Amines; Antiparkinson Agents; Botulinum Toxins; Cholinergic Antagonists; Clona | 2000 |
[Considerations in the drug treatment of parkinsonism (author's transl)].
Topics: Amantadine; Apomorphine; Bromocriptine; Dopamine; Ergolines; Extrapyramidal Tracts; Female; Humans; | 1978 |
[Therapy of tparkinson's disease. Clinical and pharmacological viewpoints].
Topics: Adrenergic beta-Antagonists; Amantadine; Bromocriptine; Histamine H1 Antagonists; Humans; Levodopa; | 1979 |
Quantitative evaluation of neuropharmacological trials.
Topics: Activities of Daily Living; Age Factors; Amantadine; Clinical Trials as Topic; Dihydroxyphenylalanin | 1974 |
17 trials available for amantadine and Tremor
| Article | Year |
|---|---|
Treatment of valproate tremors.
Topics: Amantadine; Cyproheptadine; Diphenhydramine; Humans; Propranolol; Tremor; Valproic Acid | 1983 |
[Effects of oral memantine administration on Parkinson symptoms. Results of a placebo-controlled multicenter study].
Topics: Administration, Oral; Aged; Amantadine; Clinical Trials as Topic; Female; Humans; Male; Memantine; M | 1984 |
Therapy of extrapyramidal side effects, with particular reference to persistent dyskinesia and lithium tremor.
Topics: Adolescent; Adult; Amantadine; Antipsychotic Agents; Basal Ganglia Diseases; Bromocriptine; Chronic | 1978 |
Amantadine in Parkinson's disease. A double-blind, placebo-controlled, crossover study with long-term follow-up.
Topics: Activities of Daily Living; Aged; Amantadine; Benztropine; Clinical Trials as Topic; Diphenhydramine | 1975 |
Amphetamines in the treatment of Parkinson's disease.
Topics: Aged; Amantadine; Amphetamine; Clinical Trials as Topic; Female; Humans; Isomerism; Levodopa; Male; | 1975 |
[Treatment of Parkinsonian syndrome using amantadine hydrochloride].
Topics: Adult; Aged; Amantadine; Basal Ganglia Diseases; Clinical Trials as Topic; Drug Evaluation; Electrom | 1975 |
Trial of amantadine in Parkinson's disease.
Topics: Adult; Aged; Amantadine; Clinical Trials as Topic; Constipation; Female; Hallucinations; Handwriting | 1972 |
Quantitative evaluation of neuropharmacological trials.
Topics: Activities of Daily Living; Age Factors; Amantadine; Clinical Trials as Topic; Dihydroxyphenylalanin | 1974 |
KR 339 in the treatment of Parkinsonian tremor.
Topics: Aged; Amantadine; Antiparkinson Agents; Blood Sedimentation; Bridged-Ring Compounds; Clinical Trials | 1974 |
[Kr 339 in the treatment of parkinsonian tremor].
Topics: Aged; Amantadine; Antiparkinson Agents; Bridged-Ring Compounds; Clinical Trials as Topic; Dihydroxyp | 1974 |
Parkinson disease treated with a suspected dopamine receptor agonist.
Topics: Adult; Aged; Amantadine; Aromatic Amino Acid Decarboxylase Inhibitors; Benztropine; Dihydroxyphenyla | 1974 |
Comparison of amantadine, placebo, and levodopa in Parkinson's disease.
Topics: Aged; Amantadine; Dihydroxyphenylalanine; Evaluation Studies as Topic; Female; Humans; Male; Middle | 1974 |
Use of amantadine in Parkinson's disease. Results of a double-blind trial.
Topics: Adult; Aged; Amantadine; Clinical Trials as Topic; Female; Humans; Male; Middle Aged; Parkinson Dise | 1970 |
Amantadine hydrochloride in the treatment of Parkinsonism. A controlled trial.
Topics: Activities of Daily Living; Adult; Aged; Amantadine; Analysis of Variance; Clinical Trials as Topic; | 1970 |
Amantadine in Parkinsonism. An extended prospective trial.
Topics: Aged; Amantadine; Clinical Trials as Topic; Female; Humans; Male; Middle Aged; Movement; Parkinson D | 1971 |
Amantadine hydrochloride in the treatment of parkinsonism: a placebo-controlled double-blind study.
Topics: Aged; Amantadine; Clinical Trials as Topic; Female; Gait; Humans; Jaw; Male; Middle Aged; Parkinson | 1971 |
Amantadine for Parkinson's disease.
Topics: Aged; Amantadine; Amines; Brain; Clinical Trials as Topic; Dihydroxyphenylalanine; Disability Evalua | 1971 |
33 other studies available for amantadine and Tremor
| Article | Year |
|---|---|
[Ehlers-Danlos and dystonia. Positive effects of amantadine].
Topics: Adult; Amantadine; Antiparkinson Agents; Craniocerebral Trauma; Dystonia; Ehlers-Danlos Syndrome; Fa | 2014 |
Altered mental status in a transplant patient. Amantadine toxicity.
Topics: Adult; Amantadine; Confusion; Diabetes Complications; Diabetes Mellitus, Type 1; Female; Hallucinati | 2009 |
Midbrain tremor: a tremor resistant to treatment.
Topics: Aged; Amantadine; Analgesics, Non-Narcotic; Humans; Magnetic Resonance Imaging; Male; Mesencephalon; | 2012 |
A case of temporary finger tremors due to amantadine withdrawal.
Topics: Aged, 80 and over; Amantadine; Antiparkinson Agents; Female; Fingers; Humans; Substance Withdrawal S | 2008 |
[Therapeutic concept in Parkinson disease].
Topics: Adrenergic beta-Antagonists; Amantadine; Antidepressive Agents, Tricyclic; Benzodiazepines; Bromocri | 1983 |
Amantadine in essential tremor.
Topics: Amantadine; Humans; Male; Middle Aged; Tremor | 1984 |
Drugs for Parkinson's disease reduce tremor induced by physostigmine.
Topics: Amantadine; Animals; Antiparkinson Agents; Atropine; Biperiden; Bromocriptine; Male; Physostigmine; | 1983 |
Amantadine in essential tremor.
Topics: Aged; Amantadine; Humans; Male; Middle Aged; Tremor | 1981 |
Amantadin e tremor, a 5-hydroxytryptamine-mediated response?
Topics: Amantadine; Animals; Brain; Brain Chemistry; Fenclonine; Hydroxyindoleacetic Acid; Mice; Mice, Inbre | 1975 |
Amantadine antagonism of oxotremorine effects.
Topics: Amantadine; Animals; Catalepsy; Diarrhea; Drug Antagonism; Humans; Male; Mice; Oxotremorine; Tears; | 1979 |
Vision loss associated with amantadine hydrochloride use.
Topics: Aged; Amantadine; Humans; Male; Tremor; Vision Disorders; Visual Acuity | 1977 |
The shaking patient. Diagnosis and management of tremor.
Topics: Amantadine; Carbidopa; Cerebellar Diseases; Humans; Levodopa; Parkinson Disease; Propranolol; Tremor | 1977 |
Urinary monoamine metabolite excretion in disorders of movement. Effects of amantadine and levodopa.
Topics: Amantadine; Chorea; Homovanillic Acid; Humans; Hydroxyindoleacetic Acid; Levodopa; Methylhistamines; | 1977 |
Amantadine neurotoxicity in a pediatric patient with renal insufficiency.
Topics: Adolescent; Amantadine; Central Nervous System Diseases; Creatine; Female; Graft Rejection; Hallucin | 1991 |
Comprehensive care of the patient with Parkinson's disease.
Topics: Aged; Amantadine; Bromocriptine; Carbidopa; Drug Combinations; Humans; Levodopa; Male; Muscle Rigidi | 1986 |
Amantadine may be useful in essential tremor.
Topics: Aged; Amantadine; Female; Humans; Tremor | 1986 |
Pharmacologic treatment of parkinsonian tremor.
Topics: Amantadine; Carbidopa; Drug Combinations; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Tr | 1986 |
Benign essential tremor.
Topics: Adolescent; Adult; Aged; Amantadine; Chlordiazepoxide; Ethanol; Female; Humans; Male; Mephenesin; Mi | 1972 |
Parkinsonism as a falling sickness.
Topics: Age Factors; Aged; Amantadine; Female; Gait; Humans; Levodopa; Male; Middle Aged; Movement Disorders | 1974 |
[Surgical treatment of parkisonism in the light of the modern medical therapy].
Topics: Amantadine; Dihydroxyphenylalanine; Humans; Parkinson Disease; Prognosis; Tremor | 1972 |
Amantadine in Parkinson's disease. Review of more than two years' experience.
Topics: Aged; Amantadine; Ataxia; Constipation; Depression; Diarrhea; Dihydroxyphenylalanine; Drug Synergism | 1972 |
Coloured Lilliputian hallucinations with amantadine.
Topics: Aged; Amantadine; Female; Hallucinations; Humans; Male; Parkinson Disease; Tremor; Visual Pathways | 1973 |
Interactions of L-dopa and amantadine in patients with Parkinsonism.
Topics: Amantadine; Dihydroxyphenylalanine; Drug Interactions; Evaluation Studies as Topic; Female; Homovani | 1973 |
[Epidemic tremor in chickens as a model for the testing of antiparkinson drugs].
Topics: Amantadine; Animals; Antiparkinson Agents; Chickens; Dihydroxyphenylalanine; Disease Models, Animal; | 1973 |
[Pharmacological study of amantadine, a new antiparkinson drug].
Topics: Amantadine; Amines; Animals; Antiparkinson Agents; Avoidance Learning; Brain; Catatonia; Dopamine; D | 1974 |
The therapeutic possibilities of L-dopa and amantadine in Parkinsonian patients who have undergone bilateral thalamotomy.
Topics: Adolescent; Adult; Aged; Amantadine; Child; Dihydroxyphenylalanine; Electroencephalography; Female; | 1971 |
Clinical manifestations of essential tremor.
Topics: Adult; Aged; Amantadine; Ataxia; Chlordiazepoxide; Dihydroxyphenylalanine; Female; Humans; Male; Mep | 1972 |
Depression by amantadine of drug-induced rigidity in the rat.
Topics: Amantadine; Animals; Depression, Chemical; Electrodes, Implanted; Electromyography; Motor Activity; | 1972 |
[Action of amantadine on parkinsonian tremor].
Topics: Adult; Aged; Amantadine; Ergolines; Female; Humans; Male; Middle Aged; Parkinson Disease; Promethazi | 1971 |
[Treatment of the Parkinson syndrome with amantadine].
Topics: Adult; Aged; Amantadine; Arteriosclerosis; Cognition Disorders; Dihydroxyphenylalanine; Drug Interac | 1971 |
Non-resting tremor in Parkinson's disease.
Topics: Aged; Amantadine; Dihydroxyphenylalanine; Humans; Male; Parkinson Disease; Propranolol; Tremor | 1971 |
Amantidine for relief of Parkinsonian tremor.
Topics: Amantadine; Antiviral Agents; Female; Humans; Male; Middle Aged; Parkinson Disease; Tremor | 1971 |
[The treatment of parkinsonism with amantadine].
Topics: Adult; Aged; Amantadine; Dihydroxyphenylalanine; Female; Humans; Male; Middle Aged; Parasympatholyti | 1970 |